Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A-769662 is a **potent, reversible, direct activator of AMP-activated protein kinase (AMPK)**, specifically binding to heterotrimers containing the β1 regulatory subunit. Unlike indirect AMPK activators such as metformin and AICAR, A-769662 binds at a site distinct from AMP, allosterically activating AMPK and inhibiting its dephosphorylation. It acts via the carbohydrate-binding module of the β subunit and the kinase domain interface, promoting phosphorylation of downstream AMPK targets, notably acetyl-CoA carboxylase (ACC). This leads to metabolic effects such as inhibition of fatty acid synthesis and anti-inflammatory effects in rodent models of endotoxemia and inflammatory arthritis[1][3][4][5][6][7]. Developed as a **synthetic research tool**, it has demonstrated efficacy in vitro and in preclinical animal models but is not intended for therapeutic or diagnostic human use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on A-769662.